Association Between Lipoprotein-Associated Phospholipase A2 and Cardiovascular Disease: A Systematic Review
- 1 February 2007
- journal article
- research article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 82 (2), 159-165
- https://doi.org/10.4065/82.2.159
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Heritability of Coronary Artery Calcium Quantity Measured by Electron Beam Computed Tomography in Asymptomatic AdultsCirculation, 2002
- Lp-PLA2: an emerging biomarker of coronary heart diseaseExpert Review of Molecular Diagnostics, 2002
- Inhibition of lipoprotein‐associated phospholipase A2 diminishes the death‐inducing effects of oxidised LDL on human monocyte‐macrophagesFEBS Letters, 2001
- Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic targetCurrent Opinion in Pharmacology, 2001
- Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery diseaseAtherosclerosis, 2000
- Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese populationAtherosclerosis, 2000
- Cellular Source(s) of Platelet-Activating-Factor Acetylhydrolase Activity in PlasmaBiochemical and Biophysical Research Communications, 1999
- Identification of the G994 → T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese menMetabolism, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1988